Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Nautilus Biotechnology (NAUT) Other financing activities (2020 - 2021)

Nautilus Biotechnology has reported Other financing activities over the past 2 years, most recently at $47000.0 for Q3 2021.

Quarterly results put Other financing activities at $47000.0 for Q3 2021, down 98.61% from a year ago — trailing twelve months through Jun 2022 was $47000.0 (down 99.68% YoY), and the annual figure for FY2021 was $8.1 million, changed.
Other financing activities reached $47000.0 in Q3 2021 per NAUT's latest filing, down from $6.0 million in the prior quarter.
Across five years, Other financing activities topped out at $6.0 million in Q2 2021 and bottomed at $47000.0 in Q3 2021.